Basic research

Establishment of a novel mice model of heart failure with preserved ejection fraction

  • Xiao-nan CHEN ,
  • Jun-feng ZHANG ,
  • Chang-qian WANG ,
  • Hui-li ZHANG
Expand
  • Department of Cardiology, Shanghai Ninth People′s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China

Online published: 2021-05-27

Supported by

National Natural Science Foundation of China(81570037);Guiding Medical Project of Science and Technology Committee of Shanghai Municipality(19411963300)

Abstract

Objective

·To establish a novel mice model of heart failure with preserved ejection fraction (HFpEF).

Methods

·Sixteen 8-week-old SPF grade male and female C57BL/6J mice each were randomly divided into control group or model group (n=8 per group). The model group was given high-fat diet containing 60% fat and drinking water containing 0.5 g/L Nω-nitro-L-arginine methyl ester hydrochloride (L-NAME). The control group was given routine feed and drinking water. The ratio of peak early mitral velocity to peak late mitral velocity (E/A ratio) and the ratio of peak early mitral velocity to peak early diastolic mitral annular velocity (E/E' ratio) were detected by echocardiography every two weeks to evaluate left ventricular diastolic function. At the 16th week after modeling, the myocardial hypertrophy and fibrosis were examined by Masson staining and hematoxylin-eosin staining. The levels of serum triacylglycerol (TAG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-Ch) and low-density lipoprotein cholesterol (LDL-Ch) were detected by automatic biochemical analyzer.

Results

·HFpEF appeared in the male mice at 8 weeks after high-fat diet and L-NAME administration, with a significant increase in E/A ratio and E/E′ ratio in comparison to the male control group (both P=0.000). There was no significant difference in the left ventricular ejection fraction (LVEF) between male model group and male control group. On the other hand, the female mice fed with high-fat diet and drinking water containing L-NAME also displayed obvious HFpEF after 8 weeks. E/A ratio and E/E' ratio in female model group were significantly higher than those in the female control group (P=0.000, P=0.001). There was no significant difference in LVEF between female model group and female control group. At the 16th week after modeling, both male and female mice still displayed the characteristics of HFpEF. Systolic blood pressure and diastolic blood pressure of male and female model group were significantly higher than those of respective control groups. Male or female mice with HFpEF showed obvious myocardial hypertrophy and fibrosis along with left ventricular remodeling. The serum levels of TAG, TC, HDL-Ch and LDL-Ch in the model groups were significantly higher than those in the respective control groups.

Conclusion

·High-fat feeding combined with L-NAME administration can induce HFpEF in both male and female mice.

Cite this article

Xiao-nan CHEN , Jun-feng ZHANG , Chang-qian WANG , Hui-li ZHANG . Establishment of a novel mice model of heart failure with preserved ejection fraction[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2021 , 41(5) : 565 -570 . DOI: 10.3969/j.issn.1674-8115.2021.05.002

References

1 Writing committee members, ACC/AHA task force members. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure. A report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Failure Society of America[J]. Circulation, 2016, 134(13): e282-e293.
2 Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC[J]. Eur Heart J, 2016, 37(27): 2129-2200.
3 Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction[J]. Nat Rev Cardiol, 2017, 14(10): 591-602.
4 Lam CSP, Voors AA, de Boer RA, et al. Heart failure with preserved ejection fraction: from mechanisms to therapies[J]. Eur Heart J, 2018, 39(30): 2780-2792.
5 林昊, 潘建安, 张俊峰, 等. 糖尿病、高血压和心房颤动不同治疗方案对射血分数保留心力衰竭发生的影响[J]. 上海交通大学学报(医学版), 2020, 40(10): 1402-1407.
6 Doris PA. Genetics of hypertension: an assessment of progress in the spontaneously hypertensive rat[J]. Physiol Genomics, 2017, 49(11): 601-617.
7 Methawasin M, Strom JG, Slater RE, et al. Experimentally increasing the compliance of titin through RNA binding motif-20 (RBM20) inhibition improves diastolic function in a mouse model of heart failure with preserved ejection fraction[J]. Circulation, 2016, 134(15): 1085-1099.
8 Primessnig U, Sch?nleitner P, H?ll A, et al. Novel pathomechanisms of cardiomyocyte dysfunction in a model of heart failure with preserved ejection fraction[J]. Eur J Heart Fail, 2016, 18(8): 987-997.
9 Chilian WM, Mass HJ, Williams SE, et al. Microvascular occlusions promote coronary collateral growth[J]. Am J Physiol, 1990, 258(4 Pt 2): H1103-H1111.
10 傅发源, 陈良龙. 一种新的大鼠冠状动脉微栓塞模型[J]. 中国心血管病研究杂志, 2004(4): 296-299.
11 沈成兴, 梁春, 陈良龙, 等. 经冠状动脉内注射月桂酸钠构建大鼠冠状动脉微栓塞模型[J]. 中国动脉硬化杂志, 2005, 13(4): 447-450.
12 赵胜楠, 何黎黎, 李自强, 等. 高血压合并高脂血症大鼠模型的实验研究[J]. 中国比较医学杂志, 2018, 28(2): 33-39, 89.
13 Trachanas K, Sideris S, Aggeli C, et al. Diabetic cardiomyopathy: from pathophysiology to treatment[J]. Hellenic J Cardiol, 2014, 55(5): 411-421.
14 Carbone S, Mauro AG, Mezzaroma E, et al. A high-sugar and high-fat diet impairs cardiac systolic and diastolic function in mice[J]. Int J Cardiol, 2015, 198: 66-69.
15 Ocsan RJ, Lai YN, Prabhu KV, et al. Chronic NG-nitro-l-arginine methyl ester (L-NAME) administration in C57BL/6J mice induces a sustained decrease in c-kit positive cells during development of cardiac hypertrophy[J]. J Physiol Pharmacol, 2013, 64(6): 727-736.
16 Kopincová J, Púzserová A, Bernátová I. L-NAME in the cardiovascular system: nitric oxide synthase activator?[J]. Pharmacol Rep, 2012, 64(3): 511-520.
Outlines

/